Home » HANA BEGINS TALOTREXIN PHASE II TRIALS
HANA BEGINS TALOTREXIN PHASE II TRIALS
April 3, 2006
Hana Biosciences has launched a multicenter, multinational Phase II clinical trial with Talotrexin in relapsed or refractory non-small cell lung cancer.
Talotrexin is a novel nonpolyglutamatable antifolate drug that has demonstrated improved antitumor activity in a broad spectrum of preclinical cancer models by targeting dihydrofolate reductase to prevent DNA synthesis and inhibit tumor growth.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct